Results 11 to 20 of about 104,915 (286)
New Strategies for the Treatment of Atrial Fibrillation
Pharmaceuticals, 2021 Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in the clinical practice. It significantly contributes to the morbidity and mortality of the elderly population. Over the past 25–30 years intense effort in basic research has advanced the
Norbert Jost +2 more
doaj +1 more source
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)
Therapeutic Advances in Musculoskeletal Disease, 2022 In spite of a major public health burden with increasing prevalence, current osteoarthritis (OA) management is largely palliative with an unmet need for effective treatment.
Win Min Oo, David J. Hunter
doaj +1 more source
Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
Viruses, 2022 Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and ...
Elisabetta Degasperi +2 more
doaj +1 more source
Investigational Drugs for the COVID 19 Pandemic – A Concise Review [PDF]
Pharmaceutical Sciences, 2020 The present year saw the emergence of a pandemic Corona Virus Disease of 2019 (COVID 19). The unpreparedness for the pandemic and lack of drugs/vaccine against this virus has led to a high mortality rate across the world.
Reena Sherin Parveen +2 more
doaj +1 more source
A two-year evaluation of the minutes of Investigational New Drug committee meetings
Perspectives in Clinical Research, 2021 Introduction: The Investigational New Drug (IND) committee advises the Drug Controller General of India on matters pertaining to clinical trials (CTs) of IND for clinical development.
Jeffrey Pradeep Raj +2 more
doaj +1 more source
Providing Hope: Developing a Viable Regulatory Framework for Providing Terminally Ill Patients With Adequate Access to Investigational Drugs [PDF]
, 2008 “If I die . . . I want my children to know I did everything I could.” This is a common feeling among terminally ill individuals facing death. This desire to exhaust every option often causes people to fight to receive potentially toxic and dangerous ...
Sikora, James P.
core +2 more sources
Voices in Bioethics, 2020 The need for increased access to investigational drugs has consistently been supported by the public, in spite of the fact that the Expanded Access Program (EAP), which is regulated by the Food and Drug Administration (FDA), already exists.[1] As a ...
Jacqueline Augenstein
doaj +1 more source
Journal of Clinical and Translational Science, 2023 Expanded access (EA) provides a pathway for the clinical use of investigational products (drugs, biologics, and medical devices) for patients who are without satisfactory therapeutic options and for whom a clinical trial is not available.
Misty Gravelin +9 more
doaj +1 more source
Ustekinumab for the treatment of psoriatic arthritis: an update. [PDF]
, 2014 Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic ...
Davari, Parastoo +3 more
core +1 more source
Diagnosis and Management of COVID-19 Disease [PDF]
, 2020 SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham +5 more
core +1 more source